Pregnancy in hyperprolactinemic infertile women treated with vaginal bromocriptine: Report of two cases and review of the literature

Giuseppe Ricci, Elena Giolo, Giuseppe Nucera, Cristina Pozzobon, Francesco De Seta, Secondo Guaschino

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Vaginal bromocriptine has proven safe and effective in treating hyperprolactinemic women. However, there has been no long-term clinical assessment regarding the influence of daily vaginal bromocriptine administration on the ability to conceive. This article presents two cases of successful pregnancy resulting from this alternative treatment. An infertile woman with an empty sella and hyperprolactinemia was treated with vaginal bromocriptine because of intolerance to oral administration. Prolactin levels were quickly normalized and no side effects occurred. Repeated postcoital tests during treatment proved normal. Twelve months later, the patient conceived. The therapy was discontinued during pregnancy, without complications. Although bromocriptine treatment was not resumed after delivery, postpartum prolactin levels were lower than before treatment and magnetic resonance imaging revealed an unchanged empty sella. Another patient with infertility and pituitary microadenoma with intolerance to oral dopaminergic agonists received the same treatment. Prolactin quickly fell to within the normal range. Vaginal bromocriptine was well tolerated and postcoital test results were not impaired. Tumor regression occurred and 10 months later the patient conceived. Despite bromocriptine withdrawal, no significant complications occurred during pregnancy. It can therefore be concluded that a couple's fertility does not appear to be significantly affected by the persistent local presence of bromocriptine.

Original languageEnglish
Pages (from-to)266-270
Number of pages5
JournalGynecologic and Obstetric Investigation
Volume51
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Bromocriptine
Pregnancy
Prolactin
Therapeutics
Intravaginal Administration
Hyperprolactinemia
Pregnancy Complications
Dopamine Agonists
Postpartum Period
Infertility
Fertility
Oral Administration
Reference Values
Magnetic Resonance Imaging
Neoplasms

Keywords

  • Empty sella
  • Hyperprolactinemia
  • Infertility
  • Microprolactinoma
  • Vaginal bromocriptine

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Pregnancy in hyperprolactinemic infertile women treated with vaginal bromocriptine : Report of two cases and review of the literature. / Ricci, Giuseppe; Giolo, Elena; Nucera, Giuseppe; Pozzobon, Cristina; De Seta, Francesco; Guaschino, Secondo.

In: Gynecologic and Obstetric Investigation, Vol. 51, No. 4, 2001, p. 266-270.

Research output: Contribution to journalArticle

@article{181a810455984144853bb450f178ddf9,
title = "Pregnancy in hyperprolactinemic infertile women treated with vaginal bromocriptine: Report of two cases and review of the literature",
abstract = "Vaginal bromocriptine has proven safe and effective in treating hyperprolactinemic women. However, there has been no long-term clinical assessment regarding the influence of daily vaginal bromocriptine administration on the ability to conceive. This article presents two cases of successful pregnancy resulting from this alternative treatment. An infertile woman with an empty sella and hyperprolactinemia was treated with vaginal bromocriptine because of intolerance to oral administration. Prolactin levels were quickly normalized and no side effects occurred. Repeated postcoital tests during treatment proved normal. Twelve months later, the patient conceived. The therapy was discontinued during pregnancy, without complications. Although bromocriptine treatment was not resumed after delivery, postpartum prolactin levels were lower than before treatment and magnetic resonance imaging revealed an unchanged empty sella. Another patient with infertility and pituitary microadenoma with intolerance to oral dopaminergic agonists received the same treatment. Prolactin quickly fell to within the normal range. Vaginal bromocriptine was well tolerated and postcoital test results were not impaired. Tumor regression occurred and 10 months later the patient conceived. Despite bromocriptine withdrawal, no significant complications occurred during pregnancy. It can therefore be concluded that a couple's fertility does not appear to be significantly affected by the persistent local presence of bromocriptine.",
keywords = "Empty sella, Hyperprolactinemia, Infertility, Microprolactinoma, Vaginal bromocriptine",
author = "Giuseppe Ricci and Elena Giolo and Giuseppe Nucera and Cristina Pozzobon and {De Seta}, Francesco and Secondo Guaschino",
year = "2001",
doi = "10.1159/000058062",
language = "English",
volume = "51",
pages = "266--270",
journal = "Gynecologic and Obstetric Investigation",
issn = "0378-7346",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Pregnancy in hyperprolactinemic infertile women treated with vaginal bromocriptine

T2 - Report of two cases and review of the literature

AU - Ricci, Giuseppe

AU - Giolo, Elena

AU - Nucera, Giuseppe

AU - Pozzobon, Cristina

AU - De Seta, Francesco

AU - Guaschino, Secondo

PY - 2001

Y1 - 2001

N2 - Vaginal bromocriptine has proven safe and effective in treating hyperprolactinemic women. However, there has been no long-term clinical assessment regarding the influence of daily vaginal bromocriptine administration on the ability to conceive. This article presents two cases of successful pregnancy resulting from this alternative treatment. An infertile woman with an empty sella and hyperprolactinemia was treated with vaginal bromocriptine because of intolerance to oral administration. Prolactin levels were quickly normalized and no side effects occurred. Repeated postcoital tests during treatment proved normal. Twelve months later, the patient conceived. The therapy was discontinued during pregnancy, without complications. Although bromocriptine treatment was not resumed after delivery, postpartum prolactin levels were lower than before treatment and magnetic resonance imaging revealed an unchanged empty sella. Another patient with infertility and pituitary microadenoma with intolerance to oral dopaminergic agonists received the same treatment. Prolactin quickly fell to within the normal range. Vaginal bromocriptine was well tolerated and postcoital test results were not impaired. Tumor regression occurred and 10 months later the patient conceived. Despite bromocriptine withdrawal, no significant complications occurred during pregnancy. It can therefore be concluded that a couple's fertility does not appear to be significantly affected by the persistent local presence of bromocriptine.

AB - Vaginal bromocriptine has proven safe and effective in treating hyperprolactinemic women. However, there has been no long-term clinical assessment regarding the influence of daily vaginal bromocriptine administration on the ability to conceive. This article presents two cases of successful pregnancy resulting from this alternative treatment. An infertile woman with an empty sella and hyperprolactinemia was treated with vaginal bromocriptine because of intolerance to oral administration. Prolactin levels were quickly normalized and no side effects occurred. Repeated postcoital tests during treatment proved normal. Twelve months later, the patient conceived. The therapy was discontinued during pregnancy, without complications. Although bromocriptine treatment was not resumed after delivery, postpartum prolactin levels were lower than before treatment and magnetic resonance imaging revealed an unchanged empty sella. Another patient with infertility and pituitary microadenoma with intolerance to oral dopaminergic agonists received the same treatment. Prolactin quickly fell to within the normal range. Vaginal bromocriptine was well tolerated and postcoital test results were not impaired. Tumor regression occurred and 10 months later the patient conceived. Despite bromocriptine withdrawal, no significant complications occurred during pregnancy. It can therefore be concluded that a couple's fertility does not appear to be significantly affected by the persistent local presence of bromocriptine.

KW - Empty sella

KW - Hyperprolactinemia

KW - Infertility

KW - Microprolactinoma

KW - Vaginal bromocriptine

UR - http://www.scopus.com/inward/record.url?scp=0034931489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034931489&partnerID=8YFLogxK

U2 - 10.1159/000058062

DO - 10.1159/000058062

M3 - Article

C2 - 11408739

AN - SCOPUS:0034931489

VL - 51

SP - 266

EP - 270

JO - Gynecologic and Obstetric Investigation

JF - Gynecologic and Obstetric Investigation

SN - 0378-7346

IS - 4

ER -